- Home
- ANTA vs GANX Comparison
ANTA vs GANX Comparison
Compare ANTA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | GANX |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 76.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANTA | GANX |
|---|---|---|
| Price | $2.20 | $1.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.25 | $7.20 |
| AVG Volume (30 Days) | 44.3K | ★ 494.7K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.05 | $1.21 |
| 52 Week High | $12.44 | $4.34 |
Technical Indicators
Market Signals| Indicator | ANTA | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 23.19 |
| Support Level | $2.12 | N/A |
| Resistance Level | $4.19 | $2.01 |
| Average True Range (ATR) | 0.37 | 0.10 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 12.50 | 9.51 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.